By David Tuller, DrPH
I wrote some posts last year about the ACTIB trial–a major study of telephone-delivered and web-delivered cognitive behavior therapy (TCBT and WCBT) for irritable bowel syndrome (IBS). Contrary to how the results have been framed by those with reputational and financial interests in promoting them, the study demonstrated that WCBT did not provide clinically significant benefits over treatment as usual on its two primary outcomes. At least that’s how I interpret the data.